Unknown PHASE3 INTERVENTIONAL 2-arm NCT04897854

Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer (TIMEPAN)

TIming of Start of systemIc Treatment for Asymptomatic MEtastasized PANcreatic Cancer (TIMEPAN): a Randomized Controlled Multicenter Trial

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions Metastatic Pancreas Cancer

Interventions Folfirinox

Updated 4 times since 2021 Last updated: May 18, 2021 Started: Apr 22, 2021 Primary completion: Apr 22, 2024 Completion: Apr 22, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Metastatic Pancreas Cancer and is currently ongoing. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
May 2024 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jun 2021 — May 2024 [monthly]

Recruiting PHASE3

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Data source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands